Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

6,043 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Reduced-dose WBRT combined with SRS for 1-4 brain metastases aiming at minimizing neurocognitive function deterioration without compromising brain tumor control.
Nakano T, Aoyama H, Onodera S, Igaki H, Matsumoto Y, Kanemoto A, Shimamoto S, Matsuo M, Tanaka H, Oya N, Matsuyama T, Ohta A, Maruyama K, Tanaka T, Kitamura N, Akazawa K, Maebayashi K; Japanese Radiation Oncology Study Group 13-1 (JROSG13-1) Investigators. Nakano T, et al. Among authors: matsumoto y. Clin Transl Radiat Oncol. 2022 Sep 27;37:116-129. doi: 10.1016/j.ctro.2022.09.005. eCollection 2022 Nov. Clin Transl Radiat Oncol. 2022. PMID: 36199814 Free PMC article.
Multicenter phase I/II study of chemoradiotherapy with high-dose CDDP for head and neck squamous cell carcinoma in Japan.
Matsuyama H, Yamazaki K, Okabe R, Ueki Y, Shodo R, Omata J, Sato Y, Ota H, Takahashi T, Tomita M, Yokoyama Y, Togashi T, Aoyama H, Abe E, Saijo Y, Katsura K, Soga M, Sugita T, Matsumoto Y, Tsuchida E, Horii A. Matsuyama H, et al. Among authors: matsumoto y. Auris Nasus Larynx. 2018 Oct;45(5):1086-1092. doi: 10.1016/j.anl.2018.02.008. Epub 2018 Mar 19. Auris Nasus Larynx. 2018. PMID: 29567334 Clinical Trial.
Present clinical practices of stereotactic irradiation for metastatic brain tumors in Japan: results of questionnaire survey of the Japanese Radiation Oncology Study Group (JROSG) working subgroup for neurological tumors.
Harada K, Igaki H, Abe E, Ariga T, Hayashi N, Kanemoto A, Komiyama T, Matsumoto Y, Nakano T, Onimaru R, Saito H, Sumi M, Tago M, Tanaka K, Maebayashi K, Aoyama H; Japanese Radiation Oncology Study Group (JROSG) Working Subgroup for Neurological Tumors. Harada K, et al. Among authors: matsumoto y. Int J Clin Oncol. 2018 Dec;23(6):1015-1022. doi: 10.1007/s10147-018-1313-4. Epub 2018 Jul 3. Int J Clin Oncol. 2018. PMID: 29971621
Achieving PSA < 0.2 ng/ml before Radiation Therapy Is a Strong Predictor of Treatment Success in Patients with High-Risk Locally Advanced Prostate Cancer.
Kazama A, Saito T, Takeda K, Kobayashi K, Tanikawa T, Kanemoto A, Ayukawa F, Matsumoto Y, Sugita T, Hara N, Tomita Y. Kazama A, et al. Among authors: matsumoto y. Prostate Cancer. 2019 Oct 17;2019:4050352. doi: 10.1155/2019/4050352. eCollection 2019. Prostate Cancer. 2019. PMID: 31772776 Free PMC article.
Multicenter retrospective study of stereotactic body radiotherapy for patients with previously untreated initial small hepatocellular carcinoma.
Doi Y, Nagata Y, Matsumoto Y, Numata K, Sasaki R, Yamada T, Igaki H, Imagumbai T, Katoh N, Yoshitake T, Shimizuguchi T, Fujioka D, Inoue M, Koide Y, Kimura T, Ito Y. Doi Y, et al. Among authors: matsumoto y. Hepatol Res. 2023 Aug;53(8):749-760. doi: 10.1111/hepr.13908. Epub 2023 Apr 25. Hepatol Res. 2023. PMID: 37036153
Stereotactic body radiotherapy in patients with lung tumors composed of mainly ground-glass opacity.
Onishi H, Shioyama Y, Matsumoto Y, Shibamoto Y, Miyakawa A, Suzuki G, Nishimura Y, Sasaki R, Miyawaki D, Kuriyama K, Komiyama T, Marino K, Aoki S, Saito R, Araya M, Maehata Y, Nonaka H, Tominaga L, Saito M, Sano N, Yamada S. Onishi H, et al. Among authors: matsumoto y. J Radiat Res. 2020 May 22;61(3):426-430. doi: 10.1093/jrr/rraa015. J Radiat Res. 2020. PMID: 32219316 Free PMC article.
6,043 results